Anzeige
Meldung des Tages: Das „Next Butte?“-Setup in Montana — und es ist noch immer eine $15M-Story

Ipsen News

Aktie
WKN:  A0ESMG ISIN:  FR0010259150 US-Symbol:  IPSEF Branche:  Pharmazeutika Land:  Frankreich
153,20 €
+4,40 €
+2,96%
19.03.26
Depot/Watchlist
Marktkapitalisierung *
10,01 Mrd. €
Streubesitz
27,41%
KGV
26,60
Dividende
1,40 EUR
Dividendenrendite
1,18%
Nachhaltigkeits-Score
68 %
Index-Zuordnung
-

Ipsen News

24.07.25 - GlobeNewswire
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
Cabometyx ® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of ...
23.07.25 - GlobeNewswire
Ipsen announces changes to its Executive Committee
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive ...
20.06.25 - GlobeNewswire
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade ...
31.05.25 - GlobeNewswire
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma 1 Post-hoc analysis of NAPOLI 3 study ...
07.05.25 - GlobeNewswire
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis
Additional late-​breaking data suggests up to twice as many patients treated with IQIRVO ® achieved a clinically meaningful improvement in fatigue compared to placebo after 52 ...
06.05.25 - GlobeNewswire
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation
PARIS, FRANCE, 06 May 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-​driven biopharmaceutical company, announced today the appointment of Laura Réveillon, ...
24.04.25 - GlobeNewswire
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
Elafibranor showed a favorable safety profile and demonstrated dose-​dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no ...
16.04.25 - GlobeNewswire
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
Total sales growth of 11.6% at CER 1 , or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay. Tovorafenib ...

Newssuche

Videos

newspaper
19.03.26
COUNTER HUNTER Strategie Einführung
Live-​Seminar am 29.3. ab 14 Uhr! Wie immer wird die Schulung auch aufgezeichnet und allen ... Mehr »